PCL Overview
- Founded
-
2008
- Status
-
Public
- Employees
-
72
- Stock Symbol
-
241820
- Share Price
-
$9.33
- (As of Thursday Closing)
PCL General Information
Description
PCL Inc is engaged in the development of vitro diagnostics products by SG Cap technology used in immobilizing disease biomarkers. It offers blood testing kit, multiplex antigen detection kits, and ultra-low volume non-contact liquid handling.In addition, the company offers platform services, such as sol-gel spotting service that immobilizes the customer's requested material using the SolB reagent; and SG ID service, which provides customers with a molecule of interest immobilized in the SolB reagent and identified.
Contact Information
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Drug Discovery
Stock Exchange
KRX
Primary Office
- Room 701, Star Valley
- 99, Digital-ro 9-gil, Geumcheon-gu
- Seoul, 153-777
- South Korea
+82 00-0000-0000
PCL Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $9.33 | $8.74 | $6.56 - $29.67 | $112M | 12M | 23.2K | $0.68 |
PCL Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 70,623 | 304,641 | 336,945 | 63,269 |
| Revenue | 36,866 | 40,289 | 45,467 | 31 |
| EBITDA | 11,996 | (23,415) | 17,990 | (5,836) |
| Net Income | 7,162 | (27,649) | 16,523 | (6,831) |
| Total Assets | 57,807 | 66,634 | 39,930 | 13,593 |
| Total Debt | 20,813 | 25,245 | 3,096 | 5,166 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
PCL Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
PCL Patents
PCL Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2022543050-A | Multiple biomarker simultaneous analysis device and multiple biomarker simultaneous analysis method | Pending | 30-Jul-2019 | 000000000000 | |
| EP-4006549-A1 | Device for simultaneous analysis of multiple biomarkers and method for simultaneous analysis of multiple biomarkers | Pending | 30-Jul-2019 | 0000000000 | |
| US-20220299537-A1 | Multiple biomarker simultaneous analysis apparatus and method | Pending | 30-Jul-2019 | 000000000000 | |
| EP-2518503-B1 | Sol-gel kit for preparing biochip and method for preparing biochip using the same | Active | 28-Apr-2011 | 0000000000 | |
| EP-2518503-A1 | Sol-gel kit for preparing biochip and method for preparing biochip using the same | Active | 28-Apr-2011 | G01N33/552 | 0 |
PCL Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Kim Soyoun | Founder, Chief Executive Officer & Board Member |
PCL Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| Kim Soyoun | PCL | Founder, Chief Executive Officer & Board Member | 000 0000 |
PCL Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PCL ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
20.02 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
0.000
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,784
Rank
00.00
Percentile
Technology Hardware
Industry
00 of 577
Rank
00.00
Percentile
Electronics Equipment
Subindustry
00 of 123
Rank
00.00
Percentile
